{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:54:22Z","timestamp":1791564862239,"version":"4.3.4"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.schres.2026.09.036","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:10:00Z","timestamp":1791558600000},"page":"117-120","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Development of non-dopamine active drugs for negative symptoms"],"prefix":"10.1016","volume":"298","author":[{"given":"Remy","family":"Luthringer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2026.09.036_bb0005","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.euroneuro.2024.07.005","article-title":"Strauss G Network intervention analysis indicates that roluperidone achieves its effect negative symptoms of schizophrenia by targeting avolition","volume":"87","author":"Ahmed","year":"2024","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2026.09.036_bb0010","series-title":"BJP 223.1","first-page":"321","author":"Cella","year":"2023"},{"issue":"4","key":"10.1016\/j.schres.2026.09.036_bb0015","doi-asserted-by":"crossref","DOI":"10.2217\/fnl-2020-0012","article-title":"Cariprazine in the management of negative symptoms of schizophrenia: state of the art and future perspectives","volume":"15","author":"Correll","year":"2020","journal-title":"Future Neurol."},{"key":"10.1016\/j.schres.2026.09.036_bb0025","doi-asserted-by":"crossref","DOI":"10.1038\/s41380-026-03543-1","article-title":"Interventions for negative symptoms in schizophrenia: efficacy and clinical interpretability in a meta-analysis of 451 randomized controlled trials","author":"Damiani","year":"2026","journal-title":"Mol. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2026.09.036_bb0030","doi-asserted-by":"crossref","DOI":"10.1093\/schizbullopen\/sgad001","article-title":"Remote assessment of negative symptoms of schizophrenia","volume":"4","author":"Daniel","year":"2023","journal-title":"Schizophr. Bull. Open"},{"issue":"1","key":"10.1016\/j.schres.2026.09.036_bb0035","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/schbul\/sbad145","article-title":"Targeted treatment of schizophrenia symptoms as they manifest, or continuous treatment to reduce the risk of psychosis recurrence","volume":"50","author":"Davidson","year":"2024","journal-title":"Schizophr. Bull."},{"issue":"6","key":"10.1016\/j.schres.2026.09.036_bb0045","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyaf032","article-title":"Roluperidone monotherapy, a treatment for negative symptoms in schizophrenia","volume":"28","author":"Davidson","year":"2025","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2026.09.036_bb0050","volume":"13","author":"Demyttenaere","year":"2022","journal-title":"Front. Psych."},{"key":"10.1016\/j.schres.2026.09.036_bb0055","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.euroneuro.2013.10.017","article-title":"Negative symptoms of schizophrenia: clinical features, relevance to real world functioning and specificity versus other CNS disorders","volume":"24","author":"Foussias","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2026.09.036_bb0060","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2026.4178","article-title":"FDA draft guidance for the use of Bayesian methods in clinical trials","author":"Gelman","year":"2026","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.schres.2026.09.036_bb0065","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.euroneuro.2018.03.013","article-title":"Functional connectivity of the ventral tegmental area and avolition in subjects with schizophrenia: a resting state functional MRI study","volume":"28","author":"Giordano","year":"2018","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2026.09.036_bb0070","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s40263-024-01151-7","article-title":"Negative symptoms in schizophrenia: an update on research assessment and the current and upcoming treatment landscape","volume":"39","author":"Govil","year":"2025","journal-title":"CNS Drugs"},{"issue":"8","key":"10.1016\/j.schres.2026.09.036_bb0075","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/s41583-018-0029-9","article-title":"Neuroscience of apathy and anhedonia: a transdiagnostic approach","volume":"19","author":"Husain","year":"2018","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.schres.2026.09.036_bb0080","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/s41380-023-02388-2","article-title":"Psychosis superspectrum I: nosology, etiology, and lifespan development","volume":"29","author":"Jonas","year":"2024","journal-title":"Mol. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2026.09.036_bb0085","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1176\/appi.ajp.2020.20020147","article-title":"On the origins of schizophrenia","volume":"177","author":"Kahn","year":"2020","journal-title":"Am. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2026.09.036_bb0090","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/ijnp\/pyad011","article-title":"New developments in the treatment of schizophrenia: an expert roundtable","volume":"26","author":"Kantrowitz","year":"2023","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"3","key":"10.1016\/j.schres.2026.09.036_bb0095","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1176\/appi.ajp.20250034","article-title":"Effect size deflation with increasing sample size in adjunctive trials for negative symptoms in schizophrenia: a meta-analysis and meta-regression across mechanisms of action","volume":"183","author":"Kantrowitz","year":"2026","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2026.09.036_bb0100","article-title":"Cognitive effects of MIN-101 in patients with schizophrenia and negative symptoms: results from a randomized controlled trial","volume":"79","author":"Keefe","year":"2018","journal-title":"J. Clin. Psych."},{"key":"10.1016\/j.schres.2026.09.036_bb0105","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2026.4179","article-title":"Embracing Bayesian methods in clinical trials: FDA\u2019s long-awaited draft guidance","author":"Lee","year":"2026","journal-title":"JAMA"},{"key":"10.1016\/j.schres.2026.09.036_bb0110","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-025-00667-6","article-title":"Schizophrenia","volume":"11","author":"Leucht","year":"2025","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.schres.2026.09.036_bb0115","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.schres.2024.07.008","article-title":"Negative symptoms in treatment-resistant schizophrenia and its relationship with functioning","volume":"270","author":"Lui","year":"2024","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2026.09.036_bb0120","doi-asserted-by":"crossref","DOI":"10.1017\/S0033291724003416","article-title":"Probabalistic reinforcement learning impairments predict negative symptom severity and risk for conversion in youth at clinical high-risk for psychosis","volume":"55","author":"Luther","year":"2025","journal-title":"Psychol. Med."},{"issue":"3","key":"10.1016\/j.schres.2026.09.036_bb0125","doi-asserted-by":"crossref","DOI":"10.1176\/appi.ajp.20251316","article-title":"Finding a medication for negative symptoms in schizophrenia: why so many failures?","volume":"183","author":"Marder","year":"2026","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2026.09.036_bb0135","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.schres.2026.01.018","article-title":"Negative symptoms across developmental stages in psychosis spectrum","volume":"289","author":"Mittal","year":"2026","journal-title":"Schizophr. Res."},{"issue":"3","key":"10.1016\/j.schres.2026.09.036_bb0140","article-title":"Primary and secondary negative symptoms in schizophrenia","author":"Mosolov","year":"2022","journal-title":"Front. Psychol."},{"issue":"2","key":"10.1016\/j.schres.2026.09.036_bb0145","first-page":"185","article-title":"Role of serotonin in the neurobiology of schizophrenia and association with negative symptoms","volume":"83","author":"Osugo","year":"2026","journal-title":"JAMA Psych."},{"key":"10.1016\/j.schres.2026.09.036_bb0150","doi-asserted-by":"crossref","DOI":"10.1007\/s43440-026-00852-8","article-title":"Sigma receptor ligands in selected affective disorders, psychoses, and addictions \u2013 a narrative review","author":"Piechal","year":"2026","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.schres.2026.09.036_bb0155","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.schres.2023.03.028","article-title":"Long-term effects of Roluperidone on negative symptoms of schizophrenia","volume":"255","author":"Rabinowitz","year":"2023","journal-title":"Schizophr. Res."},{"issue":"4","key":"10.1016\/j.schres.2026.09.036_bb0160","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1093\/schbul\/sbx066","article-title":"A transdiagnostic review of negative symptom phenomenology and etiology","volume":"43","author":"Strauss","year":"2017","journal-title":"Schizophr. Bull."},{"issue":"4","key":"10.1016\/j.schres.2026.09.036_bb0165","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1093\/schbul\/sbz141","article-title":"Network analysis indicates that avolition is the most central domain for the successful treatment of negative symptoms: evidence from the roluperidone randomized clinical trial","volume":"46","author":"Strauss","year":"2020","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2026.09.036_bb0170","series-title":"Negative and Cognitive Symptoms in Schizophrenia","year":"2025"},{"issue":"3","key":"10.1016\/j.schres.2026.09.036_bb0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0119852","article-title":"The association between negative symptoms, psychotic experiences and later schizophrenia: a population-based longitudinal study","volume":"10","author":"Werbeloff","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.schres.2026.09.036_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.psyneuen.2020.104879","article-title":"BDNF serum levels and cognitive improvement in drug-naive first episode patients with schizophrenia: a prospective 12-week longitudinal study","volume":"122","author":"Wu","year":"2020","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.schres.2026.09.036_bb0185","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/s41537-025-00698-8","article-title":"Antipsychotic discontinuation in schizophrenia: rational or reckless?","volume":"11","author":"Zipursky","year":"2025","journal-title":"Schizophr"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996426003300?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996426003300?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:18:26Z","timestamp":1791562706000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996426003300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":34,"alternative-id":["S0920996426003300"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2026.09.036","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of non-dopamine active drugs for negative symptoms","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2026.09.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}